Search research articles
Contact Us
Filters
Showing results (111-120 of 140) with videos related to
Page
of 14
Sort By:
Diabetes Research and Clinical Practice
|
September 4, 2020
Glycemic profile of women with normoglycemia and gestational diabetes mellitus during early pregnancy using continuous glucose monitoring system
Charandeep Singh, Yashdeep Gupta, Alpesh Goyal, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
January 27, 2007
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing
Nirat Beohar, James D Flaherty, Charles J Davidson, et al.
Blood
|
May 28, 2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson, Sundar Jagannath, Mohamad Hussein, et al.
The Lancet. Oncology
|
November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
Beatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Cancer
|
October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
James R Berenson, Sundar Jagannath, Bart Barlogie, et al.
European Journal of Haematology
|
April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
Maurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
British Journal of Haematology
|
March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
Ryan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma
Jane N Winter, David J Inwards, Stewart Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G Richardson, Hannah Briemberg, Sundar Jagannath, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 140) with videos related to
Sort By:
Page
of 14
Diabetes Research and Clinical Practice
|
September 4, 2020
Glycemic profile of women with normoglycemia and gestational diabetes mellitus during early pregnancy using continuous glucose monitoring system
Charandeep Singh, Yashdeep Gupta, Alpesh Goyal, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
January 27, 2007
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing
Nirat Beohar, James D Flaherty, Charles J Davidson, et al.
Blood
|
May 28, 2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson, Sundar Jagannath, Mohamad Hussein, et al.
The Lancet. Oncology
|
November 29, 2008
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
Beatrice J Edwards, Mrinal Gounder, June M McKoy, et al.
Cancer
|
October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
James R Berenson, Sundar Jagannath, Bart Barlogie, et al.
European Journal of Haematology
|
April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
Maurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
British Journal of Haematology
|
March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
Ryan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma
Jane N Winter, David J Inwards, Stewart Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G Richardson, Hannah Briemberg, Sundar Jagannath, et al.
Page
of 14